BioCorRx (BICX) Liabilities and Shareholders Equity (2010 - 2026)

BioCorRx has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $2.3 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $2.3 million, down 65.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.7 million (up 124.47% YoY), and the FY2025 annual result was $2.1 million, up 456.36% from the prior year.
• Liabilities and Shareholders Equity came in at $2.3 million for Q1 2026 at BioCorRx, up from $2.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $7.5 million in Q3 2025 to a low of $317444.0 in Q1 2024.
• The 5-year median for Liabilities and Shareholders Equity is $766594.0 (2022), against an average of $2.0 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 2042.45% in 2025 and tumbled 65.82% in 2026, its largest moves.
• BioCorRx's Liabilities and Shareholders Equity stood at $766594.0 in 2022, then sank by 49.27% to $388887.0 in 2023, then fell by 0.76% to $385941.0 in 2024, then jumped by 456.36% to $2.1 million in 2025, then grew by 8.27% to $2.3 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $2.3 million (Q1 2026), $2.1 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.